At ASCO 2023, we proudly unveiled the innovative results of the PHERGain clinical trial, marking a significant milestone in the field of oncology research. This study is the first to use an adaptive design that tailors treatment in the neoadjuvant/adjuvant setting for patients with HER2-positive early breast cancer. The primary aim of this trial was to assess the feasibility of a chemotherapy-free strategy based on a dual HER2 blockade with trastuzumab and pertuzumab, guided by a positron emission tomography (PET)-based, pathologic complete response (pCR)-adapted approach.
The success of the PHERGain clinical trial is not just a scientific milestone; it is also a testament to the power of collaboration. The trial involved 356 early-stage HER2-positive breast cancer patients across 45 centers in seven European countries.
Through our distinguished series titled 'Beyond Chemotherapy,' we offer our viewers a unique and enriching perspective where eleven principal investigators share their insights and analyses regarding PHERGain. This initiative not only highlights the scientific achievements of the trial but also delves into the impact and implications of these advancements in breast cancer treatment.
At MEDSIR, we wish to extend our heartfelt appreciation for the invaluable collaboration from all of the principal investigators and their unwavering commitment to conducting these enlightening interviews. Their dedication and expertise have been instrumental in this project.
Check all the interviews below:
Comments